ICL granted £150,000 to explore link between breast cancer and breastfeeding
Breast cancer is the most common cancer in the UK, accounting for 15% of all cancers
Read More
Tag: Breast Cancer Now
ICR study reveals new targeted immunotherapy to prevent spread of breast cancer
Breast cancer is responsible for around 47,000 new cases in England every year
Read More
Research identifies possible link between antibiotic use and breast cancer growth
Researchers discovered that treating mice with broad-spectrum antibiotics increased the rate at which their breast cancer tumours grew
Read More
NHS England funds first national metastatic breast cancer audit
UK-based charity Breast Cancer Now ‘proud’ of milestone after campaigning for improved data collection
Read More
NHS England breast cancer wait times are ‘deeply worrying’
All waiting time targets for breast cancer were missed in January
Read More
Researchers identify existing drug’s potential for triple negative breast cancer
Study suggests that palbociclib could be used to treat around a fifth of people with TNBC
Read More
Scientists discover mutation that causes PARP inhibitor resistance
Scientists have made a major discovery having identified a mutation that gives cancer cells resistance to AstraZeneca’s Lynparza and other PARP inhibitors.
Read More
Researchers discover ‘new line of attack’ on triple negative breast cancer
Scientists have uncovered a novel approach to fighting hard-to-treat breast cancers, triggering a new drug programme designed to develop novel targeted therapies for the disease.
Read More
Major u-turn sees Roche’s Kadcyla backed for NHS use
In a major turnaround Roche’s Kadcyla will now become routinely available on the NHS to some patients with breast cancer after a confidential deal was reached between the drug giant and NHS England.
Read More
SMC u-turn backs Roche’s Kadcyla for breast cancer
Women in Scotland will be among the first in the UK to have routine NHS access to Roche’s breast cancer drug Kadcyla after a landmark u-turn by cost regulators endorsed funding for the drug.
Read More
NICE backs Roche’s Perjeta, but bars Kadcyla
Patients with certain forms of breast cancer should be able to get routine NHS access to Roche’s Perjeta in England and Wales in the next three months following a recent final nod from NICE, but Kadcyla has been rejected by the cost regulator.
Read More
NHS patients missing out on cancer drugs
Thousands of NHS patients in the UK are missing out on access to innovative treatments that are available to patients living in some other countries of comparable wealth, finds new research by charities Breast Cancer Now and Prostate Cancer UK.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
